[Current studies of sequential methotrexate and 5-fluorouracil treatment in cancer chemotherapy]
- PMID: 3279912
[Current studies of sequential methotrexate and 5-fluorouracil treatment in cancer chemotherapy]
Abstract
This paper reviews the data on the clinical studies of sequential methotrexate and 5-fluorouracil in advanced colorectal, gastric, head and neck, and breast cancer. To date, a lot of phase II studies have been conducted, but there are many distance in each clinical data concerning response rate and side effect by the difference between their clinical methods with respect to the interval between methotrexate and 5-fluorouracil, or the dosage of each drugs. There are several reports with high response rate in those phase II studies, but randomized controlled studies recently reported have not yet confirmed the sequential effect of MTX-5-FU treatment. Therefore, it is concluded that the randomized controlled studies with the most available methods must be performed to evaluate the true efficacy of sequential methotrexate and 5-fluorouracil treatment.
Similar articles
-
[Sequential methotrexate-5-fluorouracil (MTX-5-FU) treatment of patients with advanced gastric and colorectal cancer. Sequential Methotrexate-5-FU Study Group].Gan To Kagaku Ryoho. 1987 Aug;14(8):2482-90. Gan To Kagaku Ryoho. 1987. PMID: 3619460 Japanese.
-
[Sequential methotrexate and 5-fluorouracil].Gan To Kagaku Ryoho. 1996 Dec;23(14):1907-10. Gan To Kagaku Ryoho. 1996. PMID: 8978795 Review. Japanese.
-
[Biochemical modulation with sequential methotrexate (MTX)-5-fluorouracil (5-FU) treatment].Gan To Kagaku Ryoho. 1987 May;14(5 Pt 2):1642-9. Gan To Kagaku Ryoho. 1987. PMID: 3496047 Japanese.
-
Sequential methotrexate plus 5-FU in advanced breast and colorectal cancers: a phase II study.Cancer Treat Rep. 1984 Mar;68(3):547-8. Cancer Treat Rep. 1984. PMID: 6704984
-
[Improving the anti-tumor activity of 5-fluorouracil by methotrexate].Gan To Kagaku Ryoho. 1999 Mar;26(4):431-9. Gan To Kagaku Ryoho. 1999. PMID: 10097739 Review. Japanese.
Cited by
-
Targeting serine-glycine-one-carbon metabolism as a vulnerability in cancers.Biomark Res. 2023 May 5;11(1):48. doi: 10.1186/s40364-023-00487-4. Biomark Res. 2023. PMID: 37147729 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical